parallel randomized trial

S003008

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Antipsychotic associated weight gain and severe mental illnessS003008

Design

Randomized: 28
Start year
Treatment: 24 weeks, follow-up 24 weeks
Countries
Sponsor: (not reported)
Eligibility: adults with schizophrenia on clozapine with obesity, with or without stable type 2 diabetes

Conduct and analysis

Blinding: open label
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	exenatide extended release Exenatide extended release once weekly	clozapine; lifestyle: not reported	14
A2	Standard care or no added treatment Treatment as usual	clozapine; lifestyle: not reported	14

Results

7 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

Discontinuation due to adverse events (2 lines; O26)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				0 / 14	not stated; safety; R0020689:Abstract
	A2	events				0 / 14	not stated; safety; R0020689:Abstract

Nausea (1 lines; O27A)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				8 / 14	not stated; safety; R0020689:Abstract

Vomiting (1 lines; O27B)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				7 / 14	not stated; safety; R0020689:Abstract

Diarrhea (1 lines; O27C)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				7 / 14	not stated; safety; R0020689:Abstract

Discontinuation due to gastrointestinal adverse events (2 lines; O27E)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				0 / 14	not stated; safety; R0020689:Abstract
	A2	events				0 / 14	not stated; safety; R0020689:Abstract